Skip to main content Accessibility help
×
Home
  • Print publication year: 2015
  • Online publication date: April 2015

Section 2 - General gynecology

References

1. MayKE, VillarJ, KirtleyS, KennedySH, BeckerCM. Endometrial alterations in endometriosis: a systematic review of putative biomarkers. Hum Reprod Update 2011;17:637–653.
2. WheelerJM, KnittleJD, MillerJD. Depot leuprolide versus danazol in treatment of women with symptomatic endometriosis. I. Efficacy results. Am J Obstet Gynecol 1992;167:1367–1371.
3. EskenaziB, WarnerML. Epidemiology of endometriosis. Obstet Gynecol Clin North Am 1997;24:235–258.
4. BalaschJ, CreusM, FabreguesF, et al. Visible and non-visible endometriosis at laparoscopy in fertile and infertile women and in patients with chronic pelvic pain: a prospective study. Hum Reprod 1996;11:387–391.
5. MissmerSA, HankinsonSE, SpiegelmanD, et al. Incidence of laparoscopically confirmed endometriosis by demographic, anthropometric, and lifestyle factors. Am J Epidemiol. 2004;160:784–796.
6. MartinDC. Hysterectomy for treatment of pain associated with endometriosis. J Minim Invasive Gynecol 2006;13:566–572.
7. MatalliotakisIM, CakmakH, FragouliYG, et al. Epidemiological characteristics in women with and without endometriosis in the Yale series. Arch Gynecol Obstet 2008;277:389–393.
8. JacobyVL, FujimotoVY, GiudiceLC, KuppermannM, WashingtonAE. Racial and ethnic disparities in benign gynecologic conditions and associated surgeries. Am J Obstet Gynecol 2010;202:514–521.
9. NouriK, OttJ, KrupitzB, HuberJC, WenzlR. Family incidence of endometriosis in first-, second-, and third-degree relatives: case–control study. Reprod Biol Endocrinol. 2010;11;8:85.
10. LambRNK, HoffmannR, NicholsTR. Family trait analysis: a case–control study of 43 women with endometriosis and their best friends. Am J Obstet Gynecol 1986;154:596–601.
11. BraundmeierAG, FazleabasAT. The non-human primate model of endometriosis: research and implications for fecundity. Mol Hum Reprod 2009;15:577–586.
12. SampsonJA. Perforating hemorrhagic chocolate cysts of the ovary. Arch Surg 1921;3:245–323.
13. OliveDL, HendersonDY. Endometriosis and mullerian anomalies. Obstet Gynecol 1987;69:412–415.
14. RedwineDB. “Invisible” microscopic endometriosis: a review. Gynecol Obstet Invest 2003;55:63–67.
15. LaschkeMW, GiebelsC, MengerMD. Vasculogenesis: a new piece of the endometriosis puzzle. Hum Reprod Update 2011;17:628–636.
16. BattRE, SmithRA. Embryologic theory of histogenesis of endometriosis in peritoneal pockets. Obstet Gynecol Clin North Am 1989;16:15–28.
17. RedwineDB. Was Sampson wrong?Fertil Steril 2002;78:686–693.
18. BlumenkrantzMJ, GallagherN, BashoreRA, TenckhoffH. Retrograde menstruation in women undergoing chronic peritoneal dialysis. Obstet Gynecol 1981;57:667–670.
19. GashawI, HastingsJM, JacksonKS, WinterhagerE, FazleabasAT. Induced endometriosis in the baboon (Papio anubis) increases the expression of the proangiogenic factor CYR61 (CCN1) in eutopic and ectopic endometria. Biol Reprod 2006;74:1060–1066.
20. BulunSE, UtsunomiyaH, LinZ, et al. Steroidogenic factor-1 and endometriosis. Mol Cell Endocrinol 2009;300:104–108.
21. PalombaS, OrioF Jr., MangusoF, et al. Leuprolide acetate treatment with and without coadministration of tibolone in premenopausal women with menstrual cycle-related irritable bowel syndrome. Fertil Steril 2005;83:1012–1020.
22. GaumondI, ArsenaultP, MarchandS. The role of sex hormones on formalin-induced nociceptive responses. Brain Res 2002;958:139–145.
23. MeulemanC, TomassettiC, D'HooreA, et al. Surgical treatment of deeply infiltrating endometriosis with colorectal involvement. Hum Reprod Update 2011;17:311–326.
24. KodandapaniS, PaiMV, MathewM. Umbilical laparoscopic scar endometriosis. J Hum Reprod Sci. 2011;4:150–152.
25. VercelliniP, AimiG, BusaccaM, et al. Laparoscopic uterosacral ligament resection for dysmenorrhea associated with endometriosis: results of a randomized, controlled trial. Fertil Steril 2003;80:310–319.
26. VassiliadisS, RelakisK, PapageorgiouA, AthanassakisI. Endometriosis and infertility: a multi-cytokine imbalance versus ovulation, fertilization and early embryo development. Clin Dev Immunol 2005;12:125–129.
27. SuleimanS, JohnstonDE. The abdominal wall: an overlooked source of pain. Am Fam Physician 2001;64:431–438.
28. RedwineDB, WrightJ. Laparoscopic treatment of obliteration of the cul de sac in endometriosis: long term followup. Fertil Steril 2001;76:358–365.
29. FaccioliN, ManfrediR, MainardiP, et al. Barium enema evaluation of colonic involvement in endometriosis. AJR Am J Roentgenol 2008;190:1050–1054.
30. American Fertility Society. Revised American Fertility Society classification of endometriosis 1985. Fertil Steril 1985;43:351–352.
31. Practice Committee of American Society for Reproductive Medicine. Treatment of pelvic pain associated with endometriosis. Fertil Steril 2008;90:S260–269.
32. GuzickDS, HuangLS, BroadmanBA, NealonM, HornsteinMD. Randomized trial of leuprolide versus continuous oral contraceptives in the treatment of endometriosis-associated pelvic pain. Fertil Steril 2011;95:1568–1573.
33. SchlaffWD, DugoffL, DamewoodMD, RockJA. Megestrol acetate for treatment of endometriosis. Obstet Gynecol 1990;75:646–648.
34. HullME, MoghissiKS, MagyarDF, HayesMF. Comparison of different treatment modalities of endometriosis in infertile women. Fertil Steril 1987;47:40–44.
35. VarmaR, SinhaD, GuptaJK. Non-contraceptive uses of levonorgestrel-releasing hormone system (LNG-IUS): a systematic enquiry and overview. Eur J Obstet Gynecol Reprod Biol 2006;125:9–28.
36. DawoodMY, LewisV, RamosJ. Cortical and trabecular bone mineral content in women with endometriosis: effect of gonadotropin-releasing hormone agonist and danazol. Fertil Steril 1989;52:21–26.
37. HornsteinMD, YuzpeAA, BurryKA, et al. Prospective randomized double-blind trial of 3 versus 6 months of nafarelin therapy for endometriosis associated pelvic pain. Fertil Steril 1995;63:955–962.
38. OliveDL, PrittsEA. Treatment of endometriosis. N Engl J Med 2001;345:266–275.
39. OhBR, KwonDD, ParkKS, et al. Late presentation of ureteral injury after laparoscopic surgery. Obstet Gynecol 2000;95:337–339.
40. HurdWW. Challenges to our understanding of endometriosis pain. J Minim Invasive Gynecol 2006;13:576–577.
41. AbbottJ, HaweJ, HunterD, et al. Laparoscopic excision of endometriosis: a randomized, placebo-controlled trial. Fertil Steril 2004;82:828–884.
42. HealeyM, AngWC, ChengC. Surgical treatment of endometriosis: a prospective randomized double-blinded trial comparing excision and ablation. Fertil Steril 2010;94:2536–2540.
43. NamnoumAB, HickmanTN, GoodmanSB, GehlbachDL, RockJA. Incidence of symptom recurrence after hysterectomy for endometriosis. Fertil Steril 1995;64:898–902.
44. Douay-HauserN, YazbeckC, WalkerF, et al. Infertile women with deep and intraperitoneal endometriosis: comparison of fertility outcome according to the extent of surgery. J Minim Invasive Gynecol 2011;18:622–628.

References

1. Shwartz, SM. Epidemiology of uterine leiomyomata. Clin Obstet Gynecol 2001;44:316–326.
2. ButtramVC, ReiterRC. Uterine leiomyomata: etiology, symptomatology and management. Fertil Steril 1981;36:433–445.
3. LumsdenMA, WallaceEM. Clinical presentation of uterine fibroids. Bailliere's Clin Obstet Gynaecol 1998;12:177–195.
4. CramerSF, PatelA. The frequency of uterine leiomyomas. Am J Clin Pathol 1990;94:435–438.
5. MarshallLM, SpeigelmanD, BarbieriR, et al. Variation in the incidence of uterine leiomyoma among premenopausal women by age and race. Obstet Gynecol 1997;90:967–973.
6. RossRK, PikeM, VesseyMP, et al. Risk factors for uterine fibroids: reduced risk associated with oral contraceptives. BMJ 1986;293:359–362.
7. LaughlinSK, SchorederJC, BairdDD. New directions in the epidemiology of uterine fibroids. Semin Reprod Med 2010;28:204–217.
8. FaersteinE, SzkloM, RosensheinNB. Risk factors for uterine leiomyoma: a practice-based case–control study. I. African-American heritage, reproductive history, body size, and smoking. Am J Epidemiol 2001;153:1–10.
9. BairdDD, DunsonDB, HillMC, et al. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol 2003;188:100–107.
10. GrossKL, PanhuysenCI, KleinmanMS, et al. Involvement of fumarate hydratase in nonsyndromic uterine leiomyomas: genetic linkage analysis and FISH studies. Genes Chromos Cancer 2004;41:183–190.
11. HodgeJC, CuencoK, HuyckKL, et al. Uterine leiomyomata and decreased height: a common HMGA2 predisposition allele. Hum Genet 2009;125:257–263.
12. Al-HendyA, SalamaSA. Ethnic distribution of estrogen receptor-alpha polymorphism is associated with a higher prevalence of uterine leiomyomas in black Americans. Fertil Steril 2006;86:686–693.
13. Al-HendyA, SalamaSA. Catechol-O-methyltransferase polymorphism is associated with increased uterine leiomyoma risk in different ethnic groups. J Soc Gynecol Invest 2006;13:136–144.
14. LuoX, CheginiN. The expression and potential regulatory function of microRNAs in the pathogenesis of leiomyoma. Semin Reprod Med 2008;26:500–514.
15. TaranFA, BrownHL, StewartEA. Racial diversity in uterine leiomyoma clinical studies. Fertil Steril 2010;94:1500–1503.
16. WalkerCL. Role of hormonal and reproductive factors in the etiology and treatment of uterine leiomyoma. Rec Prog Horm Res 2002;57:277–294.
17. MarshallLM, Spiegelman, GoldmanMB, et al. A prospective study of reproductive factors and oral contraceptive use in relation to the risk of uterine leiomyomata. Fertil Steril 1998;70:432–439.
18. SamadiAR, LeeNC, FlandersWD, et al. Risk factors for self reported uterine fibroids: a case control study. Am J Pub Health 1996;86:858–862.
19. RomieuI, WalkerAM, JickS. Determinants of uterine fibroids. Post Market Surveil 1991;5:119–133.
20. LumbiganonP, RugpaoS, Phandhu-FungS, et al. Protective effect of depot-medroxyprogesterone acetate on surgically treated uterine leiomyomas: a multicenter case–control study. Br J Obstet Gynaecol 1995;103:909–914.
21. WiseLA, PalmerJR, HarlowBL, et al. Reproductive factors, hormonal contraception, and risk of uterine leiomyomata in African-American women: a prospective study. Am J Epidemiol 2004;159:113–123.
22. ChenCR, BuckGM, CoureyNG, et al. Risk factors for uterine fibroids among women undergoing tubal sterilization. Am J Epidemiol 2001;153:20–26.
23. ParazziniF, NegriE, La VecchiaC, et al. Reproductive factors and risk of uterine fibroids. Epidemiology 1996;7:440–442.
24. ReinMS, BarbieriRL, Friedman, AJ. Progesterone: a critical role in the pathogenesis of uterine myomas. Am J Obstet Gynecol 1995;172:14–18.
25. SenerAB, SeckinNC, OzmenS, et al. The effects of hormone replacement therapy on uterine fibroids in postmenopausal women. Fertil Steril 1996;65:354–357.
26. YangCH, LeeJN, HsuSC, et al. Effect of hormone replacement therapy on uterine fibroids in postmenopausal women: a 3-year study. Maturitas 2002;43:35–39.
27. FedeleL, BianchiS, RaffaelliR, et al. A randomized study of the effects of tibolone and transdermal estrogen replacement therapy in postmenopausal women with uterine myomas. Eur J Obstet Gynecol Reprod Biol 2000;88:91–94.
28. de AloysioD, AltieriP, PenacchioniP, et al. Bleeding patterns in recent postmenopausal outpatients with uterine myomas: comparison between two regimens of HRT. Maturitas 1998;29:261–264.
29. ReedSD, Cushing-HaugenKL, Daling, JR, et al. Postmenopausal estrogen and progestogen therapy and the risk of uterine leiomyomas. Menopause 2004;11:214–222.
30. MarshallLM, SpiegelmanD, MansonJE, et al. Risk of uterine leiomyomata among premenopausal women in relation to body size and cigarette smoking. Epidemiology 1998;9:511–517.
31. ParazziniF, LaVecchiaC, NegriE, et al. Epidemiologic characteristics of women with uterine fibroids: case–control study. Obstet Gynecol 1988;72:853–857.
32. TerryKL, De ViroI, HankinsonSE, et al. Anthropometric characteristics and risk of uterine leiomyoma. Epidemiology 2007;18:758–763.
33. BairdDD, DunsonDB, HillMC, CousinsD, SchectmanJM. Association of physical activity with development of uterine leiomyoma. Am J Epidemiol 2007;165:157–163.
34. ParazziniF, NegriE, La VecchiaC, et al. Uterine myomas and smoking. Results from an Italian study. J Reprod Med 1996;41:316–320.
35. FlakeGP, AndersenJ, DixonD. Etiology and pathogenesis of uterine leiomyomas: a review. Environ Health Perspect 2003;111:1037–1054.
36. WiseLA, PalmerJR, HarlowBL, et al. Risk of uterine leiomyomata in relation to tobacco, alcohol and caffeine consumption in the Black Women's Health Study. Hum Reprod 2004;19:1746–1754.
37. TownsendDE, SparkesRS, BaludaMC, et al. Unicellular histogenesis of uterine leiomyomas as determined by electrophoresis of glucose-6-phosphate dehydrogenase. Am J Obstet Gynecol 1970;107:1168–1173.
38. MashalRD, FejzoMLS, FriedmanAJ, et al. Analysis of androgen receptor DNA reveals the independent clonal origins of uterine leiomyomata and the secondary nature of cytogenetic aberrations in the development of leiomyomata. Genes Chromos Cancer 1994;11:1–6.
39. HashimotoK, AzumaC, KamiuraS, et al. Clonal determination of uterine leiomyomas by analyzing differential inactivation of the X-chromosome-linked phosphoglycerokinase gene. Gynecol Obstet Invest 1995;40:204–208.
40. GrossKL, MortonCC. Genetics and the development of fibroids. Clin Obstet Gynecol 2001;44:335–349.
41. GattasGJ, QuadeBJ, NowakRA, et al. HMGIC expression in human adult and fetal tissues and in uterine leiomyomata. Genes Chromos Cancer 1999;25:316–322.
42. PedeutourF, QuadeBJ, WeremowiczS, et al. Localization and expression of the human estrogen receptor beta gene in uterine leiomyomata. Genes Chromos Cancer 1998;23:361–366.
43. KazmierczakB, Dal CinP, WanschuraS, et al. HMGIY is the target of 6p21.3 rearrangements in various benign mesenchymal tumors. Genes Chromos Cancer 1998;23:279–285.
44. TalliniG, Dal CinP, RhodenKJ, et al. Expression of HMGI-C and HMGI(Y) in ordinary lipoma and atypical lipomatous tumors: immunohistochemical reactivity correlates with karyotypic alterations. Am J Pathol 1997;151:37–43.
45. XiaoS, LuxM, ReevesR, et al. HMGI(Y) activation by chromosome 6p21 rearrangements in multilineage mesenchymal cells from pulmonary hamartoma. Am J Pathol 1997;150:901–910.
46. Dal CinP, WanschuraS, ChristiaensMR, et al. Hamartoma of the breast with involvement of 6p21 and rearrangement of HMGIY. Genes Chromos Cancer 1997;20:90–92.
47. Dal CinP, van den BergheH, et al. Involvement of 6p in an endometrial polyp. Cancer Genet Cytogenet 1991;51:279–280.
48. SornbergerKS, WeremowiczS, WilliamsAJ, et al. Expression of HMGIY in three uterine leiomyomata with complex rearrangements of chromosome 6. Cancer Gene Cytogenet 1999;114:9–16.
49. LigonAH, MortonCC. Genetics of uterine leiomyomata. Genes Chromos Cancer 2000;28:235–245.
50. VanniR, Van RoyN, LeccaU, et al. Uterine leiomyoma cytogenetics. III. Interphase cytogenetic analysis of karyotypically normal uterine leiomyoma excludes possibility of undetected trisomy 12. Cancer Genet Cytogenet 1992;62:40–42.
51. LigonAH, MortonCC. Leiomyomata: heritability and cytogenetic studies. Genes Chromos Cancer 2000;28:235–245.
52. TreloarSA, MartinNG, DennersteinL, et al. Pathways to hysterectomy: insights from longitudinal twin research. Am J Obstet Gynecol 1992;167:82–88.
53. LuotoR, KaprioJ, RutanenEM, et al. Heritability and risk factors of uterine fibroids: the Finnish Twin Cohort study. Maturitas 2000;37:15–26.
54. WinklerVDH, HoffmannW. Regarding the question of inheritance of uterine myoma. D Med Wochenschr 1938;68:235–257.
55. KurbanovaM, KorolevaAG, SergeevAS. Genetic-epidemiological analysis of uterine myoma: estimate of risk to relatives. Genetika 1989;25:1896–1898.
56. VikhlyaevaEM, KhodzhaevaZS, FantschenkoND. Familial predisposition to uterine leiomyomas. Int J Gynecol Obstet 1995;51:127–131.
57. SchwartzSM, VoigtL, TickmanE, et al. Familial aggregation of uterine leiomyomata. Am J Epidemiol 2000;151:S10.
58. SadanO, van IddekingeB, van GelderenCJ, et al. Oestrogen and progesterone receptor concentrations in leiomyoma and normal myometrium. Ann Clin Biochem 1987;24:263–267.
59. BenassayagC, LeroyMJ, RigourdV, et al. Estrogen receptors (ERalpha/ERbeta) in normal and pathological growth of the human myometrium: pregnancy and leiomyoma. Am J Physiol 1999;276:E1112–1118.
60. FolkerdEJ, NewtonCJ, DavidsonK, et al. Aromatase activity in uterine leiomyomata. J Steroid Biochem 1984;20:1195–1200.
61. SumitaniH, ShozuM, SegawaT, et al. In situ estrogen synthesized by aromatase P450 in uterine leiomyoma cells promotes cell growth probably via an autocrine/intracrine mechanism. Endocrinology 2000;141:3852–3861.
62. YammamtoT, TakamoriK, OkadaH. Estrogen biosynthesis in leiomyoma and myometrium of the uterus. Horm Metab Res 1984;16:678–679.
63. SpellacyWN, Le MaireWJ, BuhiWC, et al. Plasma growth hormone and estradiol levels in women with uterine myomas. Obstet Gynecol 1972;40:829–834.
64. MaheuxR, Lemay-TurcotL, LemayA. Daily follicle-stimulating hormone, luteinizing hormone, estradiol, and progesterone in ten women harboring uterine leiomyomas. Fertil Steril 1986;46:205–208.
65. DawoodMY, Khan-DawoodFS. Plasma insulin-like growth factor-I, CA-125, estrogen, and progesterone in women with leiomyomas. Fertil Steril 1994;61:617–621.
66. LiehrJG, RicciMJ, JefcoateCR, et al. 4-Hydroxylation of estradiol by human uterine myometrium and myoma microsomes: implications for the mechanism of uterine tumorigenesis. Proc Natl Acad Sci USA 1995;92:9220–9224.
67. BrandonDD, BetheaCL, StrawnEY, et al. Progesterone receptor messenger ribonucleic acid and protein are overexpressed in human uterine leiomyomas. Am J Obstet Gynecol 1993;169:78–85.
68. VivilleB, Charnock-JonesDS, SharkeyAM, et al. Distribution of the A and B forms of the progesterone receptor messenger ribonucleic acid and protein in uterine leiomyomata and adjacent myometrium. Hum Reprod 1997;12:815–822.
69. OtubuJA, ButtramVC, BeschNF, et al. Unconjugated steroids in leiomyomas and tumor-bearing myometrium. Am J Obstet Gynecol 1982;143:130–133.
70. TiltmanAJ. The effect of progestins on the mitotic activity of uterine fibromyomas. Int J Gynecol Path 1985;4:89–96.
71. KawaguchiD, FujiiS, KonishiI, et al. Mitotic activity in uterine leiomyomas during the menstrual cycle. Am J Obstet Gynecol 1989;160:637–641.
72. KawaguchiK, FujiiS, KonishiI, et al. Ultrastructural study of cultured smooth muscle cells from uterine leiomyoma and myometrium under the influence of sex steroids. Gynecol Oncol 1985;21:32–41.
73. MaruoT, MatsuoH, SamotoT, et al. Effects of progesterone on uterine leiomyoma growth and apoptosis. Steroids 2000;65:585–592.
74. HofmannGE, RaoCV, BarrowsGH, et al. Binding sites for epidermal growth factor in human uterine tissues and leiomyoma. J Clin Endocrinol Metab 1984;58:880–884.
75. NelsonKG, TakahashiT, BossertNL, et al. Epidermal growth factor replaces estrogen in the stimulation of female genital-tract growth and differentiation. Proc Natl Acad Sci USA 1991;88:21–25.
76. YehJ, ReinM, NowakR. Presence of messenger ribonucleic acid for epidermal growth factor (EGF) and EGF receptor demonstrable in monolayer cell cultures of myometrial and leiomyoma. Fertil Steril 1991;56:997–1000.
77. RossiMJ, CheginiN, MastersonBJ. Presence of epidermal growth factor, platelet-derived growth factor (PDGF), and their receptors in human myometrial tissue and smooth muscle cells: their action in smooth muscle cells in vitro. Endocrinology 1992;130:1716–1727.
78. LyonsRM, MosesHL. Transforming growth factors and the regulation of cell proliferation. Eur J Biochem 1990;187:467–473.
79. MatsuoH, MaruoT, SamotoT. Increased expression of Bcl-2 protein in human uterine leiomyoma and its up-regulation by progesterone. J Clin Endocrinol Metab 1997;82:293–299.
80. ValentiMT, AzzarelloG, VinanteO, et al. Differentiation, proliferation and apoptosis levels in human leiomyoma and leiomyosarcoma. J Cancer Res Clin Oncol 1998;124:93–105.
81. VuK, GreenspanDL, WuT-C, et al. Cellular proliferation, estrogen receptor, progesterone receptor, and BCL-2 expression in GnRH agonist-treated uterine leiomyomas. Hum Pathol 1998;29:359–363.
82. StewartEA. Uterine fibroids. Lancet 2001;357:293–298.
83. StovallDW. Clinical symptomatology of uterine leiomyomas. Clin Obstet Gynecol 2001;44:364–371.
84. BettocchiS, CeciO, VicinoM, et al. Diagnostic inadequacy of dilation and curettage. Fertil Steril 2001;75:803–805.
85. PronG, BennettJ, CommonA, et al. The Ontario Uterine Fibroid Embolization Trial. Part 2. Uterine fibroid reduction and symptom relief after uterine artery embolization for fibroids. Fertil Steril 2003;79:120–127.
86. RyboG, LemanJ, TibbinR. Epidemiology of menstrual blood loss. In BairdDT, MichieaP (eds.) Mechanisms of Menstrual Bleeding. New York: Raven, 1985; pp. 181–193.
87. Farrer-BrownG, BobbeilbyJOW, TarbitNH. Venous changes in the endometrium of myomatous uteri. Obstet Gynecol 1971;38:743–751.
88. YamaguchiM, MoriN. Prostaglandin production by human myometrium, uterine cervix and leiomyoma. ProsaglandinLeukot Med 1987;29:107–112.
89. AndersonJ. Factors in fibroid growth. Bailliere's Clin Obstet Gynecol 1998;12:233–238.
90. VercelliniP, VendolaN, RagniG, et al. Abnormal uterine bleeding associated with iron deficiency anemia. Etiology and role of hysteroscopy. J Reprod Med 1993;38:502–504.
91. LippmanSA, WarnerM, SamuelsS, et al. Uterine fibroids and gynecologic pain symptoms in a population-based study. Fertil Steril 2003;80:1488–1494.
92. KjerulffKH, LangenbergP, SeidmanJD, et al. Uterine leiomyomas: racial differences in severity, symptoms, and age at diagnosis. J Reprod Med 1994;41:483–490.
93. HaraT, TsuchidaM, TakaiK, et al. Ureteral obstruction in a transplanted kidney secondary to a subserous myoma uteri. Transplant 2003;75:1915–1916.
94. ReiterRC, WagnerPL, GamboneJC. Routine hysterectomy for large asymptomatic uterine leiomyomata: a reappraisal. Obstet Gynecol 1992;79:481–484.
95. ChaparalaRPC, FawoleAS, AmbroseNS, et al. Large bowel obstruction due to a benign uterine leiomyoma. Gut 2004;53:386.
96. BajekalN, LiTC. Fibroids, infertility and pregnancy wastage. Hum Reprod Update 2000;6:614–620.
97. PrittsEA. Fibroids and infertility: a systematic review of the evidence. Obstet Gynecol Surv 2001;56:483–491.
98. PrittsEA, ParkerWH, OliveDL. Fibroids and infertility: An updated systematic review of the evidence. Fertil Steril 2009;91:1215–1223.
99. UbaldiF, TournayeH, CamusM, et al. Fertility after hysteroscopic myomectomy. Hum Reprod Update 1995;1:81–90.
100. BullettiC, De ZieglerD, PolliV, et al. The role of leiomyomas in infertility. J Am Assoc Gynecol Laparosc 1999;6:441–445.
101. DonnezJ, JadoulP. What are the implications of myomas on fertility? A need for a debate? Hum Reprod 2002;17:1424–1430.
102. HartR, KhalafY, YeongCT, et al. A prospective controlled study of the effect of intramural uterine fibroids on the outcome of assisted conception. Hum Reprod 2001;16:2411–2417.
103. OliveiraFG, AbdelmassihVG, DiamondMP, et al. Impact of subserosal and intramural uterine fibroids that do not distort the endometrial cavity on the outcome of in vitro fertilization-intracytoplasmic sperm injection. Fertil Steril 2004;81:582–587.
104. CheckJH, ChoeJK, LeeG, et al. The effect on IVF outcome of small intramural fibroids not compressing the uterine cavity as determined by a prospective matched control study. Hum Reprod 2002;17:1244–1248.
105. NgEHY, HoPC. Doppler ultrasound examination of uterine arteries on the day of oocyte retrieval in patients with uterine fibroids undergoing IVF. Hum Reprod 2002;17:765–770.
106. SunkaraSK, KhairyM, El-ToukhyT, KhalafY, CoomarasamyA. The effect of intramural fibroids without uterine cavity involvement on the outcome of IVF treatment: a systematic review and meta-analysis. Hum Reprod 2010;25:418–429.
107. SurreyES. Impact of intramural leiomyomata on in-vitro fertilization-embryo transfer cycle outcome. Curr Opin Obstet Gynecol 2003;15:239–242.
108. MuramD, GilliesonM, WaltersJH. Myomas of the uterus in pregnancy: ultrasonographic follow-up. Am J Obstet Gynecol 1980;138:16–19.
109. MyersER, BarberM, CouchmanGM, et al. Management of Uterine Fibroids [Evidence Report/Technology Assessment]. Rockville, MD: Agency for Healthcare Research and Quality, 2001.
110. BensonCB, ChowJS, Chang-LeeW, et al. Outcome of pregnancies in women with uterine leiomyomas identified by sonography in the first trimester. J Clin Ultrasound 2001;29:261–264.
111. LiTC, MortimerR, CookeID. Myomectomy: a retrospective study to examine reproductive performance before and after surgery. Hum Reprod 1999;14:1735–1740.
112. CoronadoGD, MarshallLM, SchwartzSM. Complications in pregnancy, labor, and delivery with uterine leiomyomas: a population-based study. Obstet Gynecol 2000;95:764–769.
113. SalvadorE, BienstockJ, BlakemoreKJ, et al. Leiomyomata uteri, genetic amniocentesis, and the risk of second-trimester spontaneous abortion. Am J Obstet Gynecol 2002;186:913–915.
114. LanouetteJM, DiamondMP. Pregnancy in women with myoma uteri. Infert Reprod Med Clin North Am 1996;7:19–32.
115. KatzV, DottersDJ, DroegemuellerW. Complications of uterine leiomyomas in pregnancy. Obstet Gynecol 1989;73:593–596.
116. CantuariaGHC, AngioliR, FrostL, et al. Comparison of bimanual examination with ultrasound examination before hysterectomy for uterine leiomyoma. Obstet Gynecol 1998;92:109–112.
117. GoldbergJM, FalconeT, AttaranM. Sonohysterographic evaluation of uterine abnormalities noted on hysterosalpingography. Hum Reprod 1997;12:2151–2153.
118. PittawayDE, WinfieldAC, MaxsonW, et al. Prevention of acute pelvic inflammatory disease after hysterosalpingography: efficacy of doxycycline prophylaxis. Am J Obstet Gynecol 1983;147:623–626.
119. HurleyV. Imaging techniques for fibroid detection. Bailliere's Clin Obstet Gynecol 1998;12:213–224.
120. KarasickS, Lev-ToaffAS, ToaffME. Imaging of uterine leiomyomas. Am J Roentgenol 1992;158:799–805.
121. MayerDP, ShipilovV. Ultrasonography and magnetic resonance imaging of uterine fibroids. Obstet Gynecol Clin North Am 1995;22:667–725.
122. FedeleL, BianchiS, DortaM, et al. Transvaginal sonography versus hysteroscopy in the diagnosis of uterine submucous myomas. Obstet Gynecol 1991;77:745–748.
123. DueholmM, LundorfE, HansenES, et al. Accuracy of magnetic resonance imaging and transvaginal ultrasonography in the diagnosis, mapping, and measurement of uterine myomas. Am J Obstet Gynecol 2002;186:409–415.
124. de VriesLD, DijkhuizenFP, MolBW, et al. Comparison of transvaginal sonography, saline infusion sonography, and hysteroscopy in premenopausal women with abnormal uterine bleeding. J Clin Ultrasound 2000;28:217–223.
125. SylvestreC, ChildTJ, TulandiT, et al. A prospective study to evaluate the efficacy of two- and three-dimensional sonohysterography in women with intrauterine lesions. Fertil Steril 2003;79:1222–1225.
126. BrunnerM, ObrucaA, BauerP, et al. Clinical application of volume estimation based on three dimensional ultrasonography. Ultrasound Obstet Gynecol 1995;6:359–361.
127. JurkovicD. Three-dimensional ultrasound in gynecology: a critical evaluation. Ultrasound Obstet Gynecol 2002;19:109–117.
128. PretoriusDH, BeckerE, Lev-ToaffAS. Impact of sonohysterography on the management of women with uterine myomas. Ultrasound Obstet Gynecol 2001;18(Suppl):2.
129. HricakH, TscholakoffD, HeinrichsL, et al. Uterine leiomyomas: correlation of MR, histopathological findings, and symptoms. Radiology 1986;158;385–391.
130. AscherSM, JhaRC, ReinholdC. Benign myometrial conditions: leiomyomas and adenomyosis. Top Magn Reson Imaging 2003;14:281–304.
131. LefebvreG, VilosGA, AllaireC, et al. SOGC Clinical practice guidelines: The management of uterine leiomyomas. J Obstet Gynaecol Can 2003;25:396–405.
132. SchwartzLB, DiamondMP, SchwartzPE. Leiomyosarcomas: clinical presentation. Am J Obstet Gynecol 1993;168:180–183.
133. MeyerWR, MayerAR, DiamondMP, et al. Unsuspected leiomyosarcoma: treatment with a gonadotropin-releasing hormone analogue. Obstet Gynecol 1990;75:529–532.
134. CarrBR, MarshburnPB, WeatherallPT, et al. An evaluation of the effect of gonadotropin-releasing hormone analogs and medroxyprogesterone acetate on uterine leiomyomata volume by magnetic resonance imaging: a prospective, randomized, double blind, placebo-controlled, crossover trial. J Clin Endocrinol Metab 1993;76:1217–1223.
135. SivinI, SternJ. Health during prolonged use of levonorgestrel 20mcg/d and the copper TCu 380Ag intrauterine contraceptive devices: a multicenter study. International Committee for Contraception Research. Fertil Steril 1994, 61:70–77.
136. PekonenF, NymanT, LahteenmakiP, et al. Intrauterine progestin induces continuous insulin-like growth factor- binding protein-1 production in the human endometrium. J Clin Endocrinol Metab 1992;75:660–664.
137. LaurenB, ZapataLB, WhitemanMK, TepperNK, et al. Intrauterine device use among women with uterine fibroids: a systematic review. Contraception 2010;82:41–55.
138. MagalhaesJ, Mendes AldrighiJ, Rodriguesde Lima G. Uterine volume and menstrual patterns in users of the levonorgestrel-releasing intrauterine system with idiopathic menorrhagia or menorrhagia due to leiomyomas. Contraception 2007;75:193–198.
139. MakarainenL, YlikorkalaO. Primary and myoma-associated menorrhagia: role of prostaglandins and effects of ibuprofen. Br J Obstet Gynaecol 1986;93:974–978.
140. YlikorkalaO, PekonenF. Naproxen reduces idiopathic but not fibromyoma-induced menorrhagia. Obstet Gynecol 1986;68:10–12.
141. FriedmanAJ, BarbieriRL, BenacerrafBR, et al. Treatment of leiomyomata with intranasal or subcutaneous leuprolide, a gonadotropin-releasing hormone agonist. Fertil Steril 1987;48:560–564.
142. FriedmanAJ, HoffmanDI, ComiteF, et al. Treatment of leiomyomata uteri with leuprolide acetate depot: a double-blind, placebo-controlled, multicenter study. Obstet Gynecol 1991;77:720–725.
143. ChavezNF, StewartEA. Medical treatment of uterine fibroids. Clin Obstet Gynecol 2001;44:372–384.
144. ShawRW. Gonadotropin hormone-releasing hormone analogue treatment of fibroids. Bailliere's Clin Obstet Gynecol 1998;12:245–268.
145. LemayA, MaheuxR. GnRH agonists in the management of uterine leiomyoma. Infert Reprod Med Clin North Am 1996;7:33–55.
146. FarquaharC, ArrollB, EkeromaA, et al. An evidence based guideline for the management of uterine fibroids. Aust N Z J Obstet Gynaecol 2001;41:125–140.
147. DonnezJ, SchrursB, GillerotS, et al. Treatment of uterine fibroids with implants of gonadotropin-releasing hormone agonist: assessment by hysterography. Fertil Steril 1989;51:947–950.
148. WatanabeY, NakamuraG. Effects of two different doses of leuprolide acetate depot on uterine cavity area in patients with uterine leiomyomata. Fertil Steril 1995;63:487–490.
149. FriedmanAJ, DalyM, Juneau-NorcrossMJ, et al. Predictors of uterine volume reduction in women with myomas treated with a gonadotropin-releasing hormone agonist. Fertil Steril 1992;8:413–415.
150. GutmannJN, ThorntonKL, DiamondMP, et al. Evaluation of leuprolide acetate treatment on histopathology of uterine myomata. Fertil Steril 1994;61:622–626.
151. FriedmanAJ, Harrison-AtlasD, BarbieriRL, et al. A randomized, placebo-controlled, double-blind study evaluating the efficacy of leuprolide acetate depot in the treatment of uterine leiomyomata. Fertil Steril 1989;51:251–256.
152. DubuissonJB, FauconnierA, FourchotteV, et al. Laparoscopic myomectomy: predicting the risk of conversion to an open procedure. Human Reprod 2001;16:1726–1731.
153. MattaWHM, StabileI, ShawRW, et al. Doppler assessment of uterine blood flow changes in patients with fibroids receiving the gonadotropin releasing hormone agonist buserelin. Fertil Steril 1988;46:1083–1085.
154. ShawRW. Blood flow changes in the uterus induced by treatment with GnRH analogues. Hum Reprod 1996;11:27–32.
155. SerraGB, PanettaV, ColosimoM, et al. Efficacy of leuprorelin acetate depot in symptomatic fibromatous uteri: the Italian multicenter trial. Clin Ther 1992;14:57–73.
156. WestCP, LumsdenMA, BairdJT. Goserelin in the treatment of fibroids. Br J Obstet Gynecol 1992;99(Suppl):27–30.
157. HehenkampWJ, VolkersNA, BirnieE, ReekersJA, AnkumWM. Symptomatic uterine fibroids: treatment with uterine artery embolization or hysterectomy: results from the randomized clinical Embolization versus Hysterectomy (EMMY) Trial. Radiology 2008;246:823–832.
158. EdwardsRD, MossJG, LumsdenMA, et al. Committee of the Randomized Trial of Embolization versus Surgical Treatment for Fibroids. Uterine-artery embolization versus surgery for symptomatic uterine fibroids. N Engl J Med 2007;356:360–370.
159. FriedmanAJ, DalyM, Juneau-NorcrossM, et al. A prospective, randomized trial of gonadotropin-releasing hormone agonist plus estrogen-progestin or progestin “add-back” regimens for women with leiomyomata uteri. J Clin Endocrinol Metab 1993;76:1439–1445.
160. FriedmanAJ. Treatment of leiomyomata uteri with short-term leuprolide followed by leuprolide plus estrogen-progestin hormone replacement therapy for 2 years: a pilot study. Fertil Steril 1989;51:526–528.
161. MurphyAA. RU 486 in the treatment of leiomyomata uteri. Infert Reprod Med Clin North Am 1996;7:57–68.
162. DeMannoD, ElgerW, GargR, et al. Asoprisnil (J867): a selective progesterone receptor modulator for gynecological therapy. Steroids 2003;68:1019–1032.
163. ChwaliszK, LarsenL, Mattia-GoldbergC, et al. A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata. Fertil Steril 2007;87:1399–1412.
164. MaruoT, OharaN, MatsuoH, et al. Effects of levonorgestrel-releasing IUS and progesterone receptor modulator PRM CDB-2914 on uterine leiomyomas. Contraception 2007;75:S99–103.
165. UekiM, OkamatoY, TsurunagaT, et al. Endocrinological and histological changes after treatment of uterine leiomyomas with danazol or buserelin. J Obstet Gynecol 1995;21:1–7.
166. De LeoV, MorganteG, LanzettaD, et al. Danazol administration after gonadotropin-releasing hormone analogue reduces rebound of uterine myomas. Hum Reprod 1997;12:357–360.
167. TakebayashiT, FujinoY, UmesakiN, et al. Danazol suspension injected into the uterine cervix of patients with adenomyomas and myoma. Gynecol Obstet Ivest 1995;39:207–211.
168. CoutinhoEM, GoncalvesMT. Long-term treatment of leiomyomas with gestrinone. Fertil Steril 1989;51:939–946.
169. MitwallyMF, CasperRF. Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. Fertil Steril 2001;75:305–309.
170. ParsanezhadME, AzmoonM, AlborziS, et al. A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status. Fertil Steril 2010;93:192–198.
171. Eldar-GevaT, HealyDL. Other medical management of uterine fibroids. Baillieres Clin Obstet Gynaecol 1998;12:269–288.
172. JirecekS, LeeA, PavoI, et al. Raloxifene prevents the growth of uterine leiomyomas in premenopausal women. Fertil Steril 2004;81:132–136.
173. WuT, ChenXY, XieL, YangJ. Selective estrogen receptor modulators (SERMs) for uterine leiomyomas. Cochrane Database Syst Rev 2007;(4):1–22.
174. YuL, AhnagCT, CaoXM. The clinical observation of warm Needle (Ex-CA1) for uterine fibroids. J Clin Acupuncture Moxibustion 2005;21:45.
175. LiuJP, YangH, XiaY, CardiniF. Herbal preparations for uterine fibroids. Cochrane Database Syst Rev 2013;(4):CD005292.
176. RavinaJH, HerbreteauD, Ciraru-VigneronN, et al. Arterial occlusion to treat uterine myomata. Lancet 1995;346:671–672.
177. NickolicB, SpiesJB, LundstenMJ, et al. Patient radiation dose associated with uterine artery embolization. Radiology 2000;214:121–125.
178. WalkerWJ, PelageJP, SuttonC. Fibroid embolization. Clin Radiol 2002;57:325–331.
179. TropeanoG, DiStasiC, AmorosoA, et al. Incidence and risk factors for clinical failure of uterine leiomyoma embolization. Obstet Gynecol 2012;120:269–276.
180. GuptaJK, SinhaAS, LumsdenMA, HickeyM. Uterine artery embolization for symptomatic uterine fibroids. Cochrane Database Syst Rev 2012;(5):CD005073.
181. GoldbergJ, PereiraL, BerghellaV. Pregnancy after uterine artery embolization. Obstet Gynecol 2002;100:869–872.
182. ChenYJ, WangPH, YuanCC, et al. Pregnancy following treatment of symptomatic myomas with laparoscopic bipolar coagulation of uterine vessels. Hum Reprod 2003;18:1077–1081.
183. HomerH, SaridoganE. Uterine artery embolization for fibroids is associated with an increased risk of miscarriage. Fertil Steril 2010;94:324–930.
184. Worthington-KirschR, SpiesJB, MyersER, for the Fibroid Investigators. The Fibroid Registry for outcomes data (FIBROID) for uterine embolization: short term outcomes. Obstet Gynecol 2005;106:52–59.
185. VashishtA, StuddJ, CareyA, et al. Fatal septicaemia after fibroid embolization. Lancet 1999;354:307–308.
186. PelageJP, Le DrefO, SoyerP, et al. Fibroid-related menorrhagia: treatment with superselective embolization of the uterine arteries and mid term follow-up. Radiology 2000;215:428–431.
187. ChrismanHB, SakerMB, RyuR, et al. The impact of uterine fibroid embolization on resumption of menses and ovarian function. J Vasc Interv Radiol 2000;11:699–703.
188. Czeyda-PommersheimF, MageeST, CooperC, HahnWY, SpiesJB. Venous thromboembolism after uterine fibroid embolization. Cardiovasc Interv Radiol 2003;14:1147–1153.
189. HeinigJ, NeffA, CirkelU, et al. Recurrent leiomyomatosis peritonealis disseminata after hysterectomy and bilateral salpingo-oophorectomy during combined hormone replacement therapy. Eur J Obstet Gynecol Reprod Biol 2003;111:216–218.
190. CarlsonKJ, MillerBA, FowlerFJ. The Maine Women's Health Study: I. Outcomes of hysterectomy. Obstet Gynecol 1994;83:556–565.
191. DwyerN, HuttonJ, StirratGM. Randomised controlled trial comparing endometrial resection with abdominal hysterectomy for the surgical treatment of menorrhagia. Br J Obstet Gynaecol 1993;100:237–243.
192. ManyondaI, SinthamoneyaE, BelliAM. Controversies and challenges in the modern management of uterine fibroids. BJOG 2004;111:95–102.
193. PintoI, ChimenoP, RomoA, et al. Uterine fibroids: uterine artery embolization versus abdominal hysterectomy for treatment: a prospective, randomized, and controlled clinical trial. Radiology 2003;226:425–431.
194. HwangJL, SeowKM, TsaiYL, et al. Comparative study of vaginal, laparoscopically assisted vaginal and abdominal hysterectomies for uterine myoma larger than 6 cm in diameter or uterus weighing at least 450 g: a prospective randomized study. Acta Obstet Gynecol Scand 2002;81:1132–1138.
195. RibeiroSC, RibeiroRM, SantosNC, et al. A randomized study of total abdominal, vaginal and laparoscopic hysterectomy. Int J Gynecol Obstet 2003;83:37–43.
196. LearmanLA, SummittRL Jr., VarnerRE, et al. A randomized comparison of total or supracervical hysterectomy: surgical complications and clinical outcomes. Obstet Gynecol 2003;102:453–462.
197. VollenhovenBJ, LawrenceAS, HealyDL. Uterine fibroids: a clinical review. Br Obstet Gynaecol 1990;97:285.
198. WallachEE. Myomectomy. In ThompsonJD, RockJA (eds.) Telinde's Operative Gynecology. Philadelphia, PA: Lippincott-Raven, 1992, pp. 647–660.
199. LaMorteAL, LalwaniS, DiamondMP. Morbidity associated with abdominal myomectomy. Obstet Gynecol 1993;82:897.
200. IversonRE, ChelmowD, StrohbehnK, et al. Relative morbidity of abdominal hysterectomy and myomectomy for management of uterine leiomyomas. Obstet Gynecol 1996;88:415–419.
201. RosettiA, SizziO, SoronnaL, et al. Long-term results of laparoscopic myomectomy: recurrence rate in comparison with abdominal myomectomy. Hum Reprod 2001;16:770–774.
202. FauconnierA, ChapronC, Babaki-Fard, et al. Recurrence of leiomyomata after myomectomy. Hum Reprod Update 2000;6:595–602.
203. StewartEA, FaurEA, WiseLA, et al. Predictors of subsequent surgery for uterine leiomyomata after abdominal myomectomy. Obstet Gynecol 2002;99:426–432.
204. NisolleM, SmetsM, GillerotS, et al. Laparoscopic myolysis with the Nd:YAg laser. J Gynecol Surg 1993;9:95–99.
205. PhillipsDR, NathonsonHG, MilimSJ, et al. Experience with laparoscopic leiomyoma coagulation and concomitant operative hysteroscopy. J Am Assoc Gynecol Laparosc 1997;4:425–433.
206. VilosG, DalyL, TseB. Pregnancy outcome after laparoscopic myolysis. J Am Assoc Gynecol Laparosc 1998;5:289–292.
207. GlasserMH, ZimmermanJD. The hydrothermablator system for management of menorrhagia in women with submucous myomas: 12- to 20-month follow-up. J Am Assoc Gynecol Laparosc 2003;10:521–527.
208. LeeBB. Radiofrequency ablation of uterine leiomyomata: a new minimally invasive hysterectomy alternative. Obstet Gynecol 2002;99:9S.
209. ChudnoffSG, BermanJM, LevineDJ, et al. Outpatient procedure for the treatment and relief of symptomatic uterine myomas. Obstet Gynecol 2013;121:1075–1082.
210. MyersER, BarberMD, Gustilo-AshbyT, et al. Management of uterine leiomyomata: what do we really know?Obstet Gynecol 2002;100:8–17.

References

1. Centers for Disease Control and Prevention. Ectopic Pregnancy: United States, 1990–1992. MMWR 1995;44:46–48.
2. GoldnerTE, LawsonHW, XiaZ, AtrashJK. Surveillance for ectopic pregnancy-United States, 1970–1989. MMWR Surveill Summ 1993;42:73–85.
3. CreangaAA, Shapiro-MendozaCK, et al. Trends in ectopic pregnancy mortality in the United States. Obstet Gynecol 2011;117:837–843.
4. SkejeldestadFE, HadguA, ErikssonN. Epidemiology of repeat ectopic pregnancy: a population-based prospective cohort study. Obstet Gynecol 1998;91:129–135.
5. ShermanD, LangerR, SadovskyG, BukovskyI, CaspiE. Improved fertility following ectopic pregnancy. Fertil Steril 1982;37:497–502.
6. PoulyJL, MahnesH, MageG, CanisM, BruhatMA. Conservative laparoscopic treatment of 321 ectopic pregnancies. Fertil Steril 1986;46:1093–1097.
7. MaikinenJI, SalmiTA, NikkanenVPJ. Encouraging rates of fertility after ectopic pregnancy. Int J Fertil 1989;34:46–51.
8. AnkumWM, MolBW, van der VeenF, BossuytRM. Risk of factors for ectopic pregnancy: a meta-analysis. Fertil Steril 1996;65:1093–1099.
9. SivinI. Dose- and age-dependent ectopic pregnancy risks with intrauterine contraception. Obstet Gynecol 1991;78:291–298.
10. SivinI, SternJ. Health during prolonged use of levonorgestrel 20 micrograms/d and the copper TCu 380Ag intrauterine contraceptive devices: a multicenter study. International Committee for Contraception Research (ICCR). Fertil Steril 1994;61:70–77.
11. XiongX, BuekensP, WollastE. IUD use and the risk of ectopic pregnancy: a meta-analysis of case–control studies. Contraception 1995;52:23–34.
12. HillisSD, JoesoefR, MarchbanksPA, et al. Delayed care of pelvic inflammatory disease as a risk factor for impaired fertility. Am J Obstet Gynecol 1993;168:1503–1509.
13. NessRB, SoperDE, HolleyRL, et al. Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results for the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Randomized Trial. Am J Obstet Gynecol 2002;186:929–937.
14. PetersonHB, XiaZ, HughesJM, et al. The risk of ectopic pregnancy after tubal sterilization. US Collaborative Review of Sterilization Working Group. N Engl J Med 1997;336:762–767.
15. HillisSD, MarchbanksPA, TylorLR, PetersonHB. Poststerilization regret: findings from the United States Collaborative Review of Sterilization. Obstet Gynecol 1999;93:889–895.
16. HulkaJF, HalmeJ. Sterilization reversal: results of 101 attempts. Am J Obstet Gynecol 1988;159:767–774.
17. ClaytonHB, SchieveLA, PetersonHB, et al. Ectopic pregnancy risk with assisted reproductive technology procedures. Obstet Gynecol 2006;107:595–604.
18. ClelandK, RaymondE, TrussellJ, ChengL, ZhuH. Ectopic pregnancy and emergency contraceptive pills: a systematic review. Obstet Gynecol 2010;115:1263–1266.
19. Centers for Disease Control and Prevention. US medical eligibility criteria for contraceptive use, 2010. MMWR 2010;59(RR-4):1–86.
20. BjornnsonHM, GraffeoCS, DavisSS. Ruptured ectopic pregnancy after previously confirmed tubal occlusion by the Essure procedure. Ann Emerg Med 2011;57:310–311.
21. SivinI, CampodonicoI, KiriwatO, et al. The performance of levonorgestrel rod and Norplant contraceptive implants: a 5 year randomized study. Hum Reprod 1998;13:3371–3378.
22. KendrickJS, TierneyEF, LawsonHW, et al. Previous cesarean delivery and the risk of ectopic pregnancy. Obstet Gynecol 1996;87:297–301.
23. AtashHK, StraussLT, KendrickJS, SkjeldestadFE, AhnYW. The relation between induced abortion and ectopic pregnancy. Obstet Gynecol 1997;89:512–518.
24. BarnhartK, EspositoM, CoutifarisC. An update on the medical treatment of ectopic pregnancy. Obstet Gynecol Clin North Am 2000;27:653–667.
25. WestromL. Effect of acute pelvic inflammatory disease on fertility. Am J Obstet Gynecol 1975;121:707–713.
26. Arias-StellaJ. The Arias–Stella reaction: facts and fancies four decades after. Adv Anat Pathol 2002;9:12–23.
27. KadarN, RomeroR. Further observations on serial human chorionic gonadotropin patterns in ectopic pregnancies and spontaneous abortions. Fertil Steril 1988;50:367–370.
28. KadarN, CaldwellBY, RomeroR. A method of screening for ectopic pregnancy and its indications. Obstet Gynecol 1981;58:162–165.
29. AhmedA, TomBDM, CalabreseP. Ectopic pregnancy diagnosis and the pseudo-sac. Fertil Steril 2004;81:1225–1228.
30. KirchlerHC, SeebacherS, AlgeAA, et al. Early diagnosis of tubal pregnancy: changes in tubal blood flow evaluated by endovaginal color Doppler sonography. Obstet Gynecol 1993;82:561–565.
31. StovallTG, LingFW, CarsonSA, et al. Serum progesterone and uterine curettage in differential diagnosis of ectopic pregnancy. Fertil Steril 1992;57:456–458.
32. MolBW, LijmerJG, AnkumWM, van der VeenF, BossuytPM. The accuracy of single serum progesterone measurement in the diagnosis of ectopic pregnancy: a meta-analysis. Hum Reprod 1998;13:3220–3227.
33. RauschME, SammelMD, TakacsP, et al. Development of a multiple marker test for ectopic pregnancy. Obstet Gynecol 2011;117:573–581.
34. LindahlB, AhlgrenM. Identification of chorion villi in abortion specimens. Obstet Gynecol 1986;67:79–81.
35. RomeroR, CopelJA, KadarN, et al. Value of culdocentesis in the diagnosis of ectopic pregnancy. Obstet Gynecol 1985;65:519–522.
36. StovallTG, LingFW. Ectopic pregnancy: diagnostic and therapeutic algorithms minimizing surgical intervention. J Reprod Med 1993;38:807–810.
37. StovallTG, LingFW, GrayLA. Single-dose methotrexate for treatment of ectopic pregnancy. Obstet Gynecol 1991;77:754–757.
38. StovallTG, LingFW, BusterJE. Outpatient chemotherapy of unruptured ectopic pregnancy. Fertil Steril 1989;51:435–438.
39. BarnhartKT, GosmanG, AshbyR, SammelM. The medical management of ectopic pregnancy: a meta-analysis comparing “single dose” and “multidose” regimens. Obstet Gynecol 2003;101:778–784.
40. BarnhartK, HummelAC, SammelMD, et al. Use of “2-dose” regimen of methotrexate to treat ectopic pregnancy. Fertil Steril 2007;87:250–256.
41. American Congress of Obstetricians and Gynecologists. ACOG Practice Bulletin No.94: medical management of ectopic pregnancy. Obstet Gynecol 2008;111:1479–1485.
42. SeeberBE, BarnhartKT. Suspected ectopic pregnancy. Obstet Gynecol 2006;107:399–413.
43. GrayDT, ThorburnJ, LundorffP, StrandellA, LindbloomB. A cost-effectiveness study of a randomized trial of laparoscopy versus laparotomy for ectopic pregnancy. Lancet 1995;345:1139–1143.
44. LundorffP, ThorburnJ, LindbloomB. Fertility outcome after conservative surgical treatment of ectopic pregnancy evaluated in randomized trial. Fertil Steril 1992;57:998–1002.
45. SeiferDB, GutmannJN, GrantWD, KampsCA, DeCherneyAH. Comparison of persistent ectopic pregnancy after laparoscopic salpingostomy versus salpingectomy at laparotomy for ectopic pregnancy. Obstet Gynecol 1993;81:378–382.
46. YaoM, TulandiT. Current status of surgical and nonsurgical management of ectopic pregnancy. Fertil Steril 1997;67:421–433.
47. OrySJ, NnadiE, HerrmannR, et al. Fertility after ectopic pregnancy. Fertil Steril 1993;60:231–235.
48. StrohmerH, ObrucaA, LehnerR, et al. Successful treatment of a heterotopic pregnancy by sonographically guided instillation of hyperosmolar glucose. Fertil Steril 1998;69:149–151.
49. KorhonenJ, StenmanUH, YlotaloP. Serum human chorionic gonadotropin dynamics during spontaneous resolution of ectopic pregnancy. Fertil Steril 1994;61:632–636.
50. ParenteJT, OuCS, LevyJ, et al. Cervical pregnancy analysis: a review and report of five cases. Obstet Gynecol 1983;62:79–82.
51. ComstockC, HustonK, LeeW. The ultrasonographic appearance of ovarian ectopic pregnancies. Obstet Gynecol 2005;105:42–45.
52. SpiegelbergO. Zur Gosuistik de Ovarialscwangerschalt. Arch Gynackol 1973;13:73–76.
53. AtrashHK, FriedeA, HogueCJR. Abdominal pregnancy in the United States: frequency and maternal mortality. Obstet Gynecol 1987;69:333.
54. MartinJN Jr., SessumsJK, MartinRW, et al. Abdominal pregnancy: current concepts of management. Obstet Gynecol 1988;71:549–557.
55. ClaytonHB, ShieveLA, PetersonHB, et al. A comparison of heterotopic and intrauterine-only pregnancy outcomes after assisted reproductive technologies in the United States 1999–2002. Fertil Steril 2007;87:303.
56. AshA, SmithA, MaxwellD. Cesarean scar pregnancy. BJOG 2007;114:253–263.
57. JacksonP, BarrowcloughIW, FranceJT, et al. A successful pregnancy following total hysterectomy. Br J Obstet Gynaecol 1980;87:353–355.

References

1. Moyal-BarraccoM, LeibowitchM, OrthG. Vestibular papillae of the vulva. Lack of evidence for human papillomavirus etiology. Arch Dermatol 1990;126:1594–1598.
2. MichelettiL, PretiM, BogliattoF, et al. Vulvology: a proposal for a multidisciplinary subspecialty. J Reprod Med 2002;47:715–717.
3. RidleyCM, FrankmanO, JonesIS, et al. New nomenclature for vulvar disease: International Society for the Study of Vulvar Disease. Hum Pathol 1989;20:495–496.
4. WilkinsonEJ, KnealeB, LynchPJ. Report of the ISSVD terminology Committee. J Reprod Med 1986;31:973–974.
5. LynchPJ, Moyal-BarroccoM, BogliattoF, MichelitteL, ScurryJ. 2006 ISSVD classification of vulvar dermatoses pathologic subsets and their clinical correlates. J Reprod Med 2007;52:3–9.
6. SideriM, JonesRW, WilkinsonEJ, et al. Squamous vulvar intraepithelial neoplasia: 2004 modified terminology, ISSVD Vulvar Oncology Subcommitee. J Reprod Med 2005;50:807.
7. MartinoJL, VermundSH. Vaginal douching: evidence for risks or benefits to women's health. Epidemiol Rev 2002;24:109–124.
8. SihvoS, AhonenR, MikanderH, et al. Self medication with vaginal antifungal drugs: physicians' experience and women's utilization patterns. Family Pract 2000;17:145–149.
9. LewisFM, ShahM, HarringtonCI. Vulval involvement in lichen planus: a study of 37 women. Br J Dermatol 1996;135:89–91.
10. SadownikLA. Clinical profile of vulvodynia patients: a prospective study of 300 patients. J Reprod Med 2000;45:679–684.
11. EvaLJ, ReidW, MacLeanA, et al. Assessment of response to treatment in vulvar vestibulitis syndrome by means of the vulvar algesiometer. Am J Obstet Gynecol 1999;181:99–102.
12. HandaV, SticeC. Fungal culture findings in cyclic vulvitis. Obstet Gynecol 2000;96:301–303.
13. MargessonLJ. Contact dermatitis of the vulva. Dermatol Ther 2004;17:20–27.
14. CroneAM, StewartEJ, WojnarowskaF, et al. Aetiological factors in vulvar dermatitis. J Eur Acad Dermatol Venereol 2000;14:181–186.
15. VirgiliA, CorazzaM, BacilieriS, et al. Contact sensitivity in vulval lichen simplex chronicus. Contact Dermatitis 1997;37:296–297.
16. ChowETY. Multiple corticosteroid allergies. Aus J Dermatol 2001;42:62–63.
17. GoldsteinAT, MarinoffSC, ChristopherK, SrodonM. Prevalence of vulvar lichen sclerosus in a general gynecology practice. J Reprod Med 2005 Jul 50:477–480.
18. FischerGO. The commonest causes of symptomatic vulvar disease: a dermaologist's perspective. Australas J Dermatol 1996;37:12–18.
19. Meyrick-ThomasRH, RidleyCM, MacGibbonDH, et al. Lichen sclerosus et atrophicus and autoimmunity: a study of 350 women. Br J Dermatol 1988;108:41.
20. SideriM, OrigoniM, SpinaciL, et al. Topical testosterone in the treatment of vulvar lichen sclerosus. Int J Gynecol Obstet 1994;46:53–56.
21. BraccoGL, CarliP, SonniL, et al. Clinical and histologic effects of topical treatments of vulval lichen sclerosus, a critical evaluation. J Reprod Med 1993;38:37–40.
22. GoldsteinA, MarinoffS, ChistopherK. Pimecrolimus for the treatment of vulvar lichen sclerosus. J Reprod Med 2004;49:778–780.
23. KunstfeldR, ReinhardK, StinglG, et al. Successful treatment of vulvar lichen sclerosus with topical tacrolimus. Arch Dermatol 2003;139:850–852.
24. BohmM, FrielingU, LugerT, et al. Successful treatment of anogenital lichen sclerosus with topical tacrolimus. Arch Dermatol 2003;139:922–924.
25. CarliP, CattaneoA, De MagnisA, et al. Squamous cell carcinoma arising in vulvar lichen sclerosus: a longitudinal cohort study. Eur J Cancer Prev 1995;4:491–495.
26. CarliP, De MagnisA, MannoneF, et al. Vulvar carcinoma associated with lichen sclerosus, experience at the Florence Italy vulvar clinic. J Reprod Med 2003;48:313–317.
27. EdwardsL. Vulvar lichen planus. Arch Dermatol 1989;125:1677–1680.
28. EdwardsL, FriedrichE. Desquamative vaginitis: lichen planus in disguise. Obstet Gynecol 1988;71:832–836.
29. AndersonM, KutznerS, KaufmanR. Treatment of vulvovaginal lichen planus with vaginal hydrocortisone suppositories. Obstet Gynecol 2002;100:359–362.
30. ByrdJ, DavisM, RogersR. Recalcitrant symptomatic vulvar lichen planus, response to topical tacrolimus. Arch Dermatol 2004;140:715–720.
31. JensenJ, BirdM, LeClairC. Patient satisfaction after the treatment of vulvovaginal erosive lichen planus with topical clobetasol and tacrolimus: a survey study. Am J Obstet Gynecol 2004;190:1759–1765.
32. Moyal-BarraccoM, LynchP. 2003 ISSVD terminology and classification of vulvodynia. J Reprod Med 2004;49:772–777.
33. FriedrichEG. Vulvar vestibulitis syndrome. J Reprod Med 1987;32:110–114.
34. HarlowB, StewartS.Apopulation-based assessment of chronic unexplained vulvar pain: Have we underestimated the prevalence of vulvodynia? JAMA 2003;58:82–88.
35. HaefnerH, CollinsM, DavisG, et al. The vulvodynia guideline. J Lower Genital Tract Disease 2005;9:40–51.
36. PykaRE, WilkinsonEJ, FriedrichEG, et al. The histopathology of vulvar vestibulitis syndrome. Int J Gynecol Pathol 1988;7:249–257.
37. ChadhaS, GianottenWL, DrogendijkAC. Histopathologic features of vulvar vestibulitis. Int J Gynecol Pathol 1998;17:7–11.
38. PraysonR, StolerM, HartW. Vulvar vestibulitis, a histopathologic study of 36 cases, including human papillomavirus in situ hybridization analysis. Am J Surg Pathol 1995;19:154–160.
39. LundquistE, HoferP, OlofssonJ. Is vulvar vestibulitis an inflammatory condition? A comparison of histological findings in affected and healthy women. Acta Derm Venereol 1997;77:319–322.
40. WestromLV, WillenR. Vestibular nerve fiber proliferation in vulvar vestibulitis syndrome. Obstet Gynecol 1998;91:572–576.
41. Bohm-StarkeN, HilligesM, FalconerC. Increased intraepithelial innervation in women with vulvar vestibulitis syndrome. Gynecol Obstet Invest 1998;46:256–260.
42. EdwardsL. New concepts in vulvodynia. Am J Obstet Gynecol 2003;189:S24–S30.

References

1. RohrerM, MichelottiM, NahrwoldD. A prospective evaluation of the efficacy of preoperative coagulation testing. Ann Surg 1989;208:554–557.
2. LamersR, van EngelshovenJ, PfaffA. Once again, the routine preoperative thorax photo. Ned Tijdschr Geneeskd 1989;133:2288–2291.
3. LoderR. Routine preoperative chest radiography. Anesthesiology 1987;66.
4. PiscitelliJ, SimelD, AddisonW. Who should have intravenous pyelograms before hysterectomy for benign disease?Obstet Gynecol 1987;69:541–545.
5. EasleyH, HammondC. Informed consent in obstetrics and gynecology. Postgrad Obstet Gynecol 1986;10:1–12.
6. KaramanliogluB, TuranA, MemisD, TureM. Preoperative oral rofecoxib reduces postoperative pain and tramadol consumption in patients after abdominal hysterectomy. Anesth Analg 2004;98:1039–1043.
7. MeyerR. Rofecoxib reduces perioperative morphine consumption for abdominal hysterectomy and laparoscopic gastric banding. Anaesth Intensive Care 2002;30:389–390.
8. SinatraR, ShenQ, HalaszynskiT, et al. Preoperative rofecoxib oral suspension as an analgesic adjunct after lower abdominal surgery: the effects on effort dependent pain and pulmonary function. Anesth Analg 2004;98:135–140.
9. NgA, TempleA, SmithG, EmemboluJ. Early analgesic effects of parecoxib versus ketorolac following laparoscopic sterilization: a randomized controlled trial. Br J Anaesth 2004;92:846–849.
10. RawalN. Epidural and spinal agents for postoperative analgesia. Surg Clin North Am 1999;79:313–344.
11. TanosV, RojanskyN. Prophylactic antibiotics in abdominal hysterectomy. J Am Coll Surg 1994;179:593–600.
12. American Congress of Obstetricians and Gynecologists. ACOG Practice Bulletin 104: Antibiotic Prophylaxis for Gynecologic Procedures. Washington, DC: American Congress of Obstetricians and Gynecologists, 2009, pp. 1–10.
13. DellingerE, GrossP, BarrettT, et al. Quality standard for antimicrobial prophylaxis in surgical procedures. Infectious Diseases Society of America. Clin Infect Dis 1994;18:422–427.
14. HemsellD, JohnsonE, HemsellP, et al. Cefazolin is inferior to cefotetan as single-dose prophylaxis for women undergoing elective total abdominal hysterectomy. Clin Infect Dis 1995;20:677–684.
15. McFarlandL, SurawiczC, GreenbergR, et al. Prevention of beta-lactam-associated diarrhea by Saccharomyces boulardii compared with placebo. Am J Gastroenterol 1995;90:439–448.
16. IdsoeO, GutheT, WillcoxR, de WeekA. Nature and extent of penicillin side-reactions, with particular reference to fatalities from anaphylactic shock. Bull World Health Organ 1968;38:159–188.
17. HemsellD. Prophylactic antibiotics in gynecologic and obstetric surgery. Rev Infect Dis 1991;13(Suppl 10):S821–S841.
18. BurkeJF. Preoperative antibiotic. Surg Clin North Am 1963;43:665–676.
19. DieterAA, AmundsenCL, EdenfieldAL, et al. Oral antibiotics to prevent postoperative urinary tract infection. Obstet Gynecol 2014;123:96–103.
20. WilsonW, TaubertKA, GewitzM, et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawaski Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardio-vascular Surgery and Anesthesia, and the Quality of Care and Outcomes research Interdisciplinary Working Group. Circulation 2007;116:1736–1754.
21. NicholsR, SmithJ, GarciaR, et al. Current practices of preoperative bowel preparation among North American colorectal surgeons. Clin Infec Dis 1997;24:606–619.
22. ZmoraO, MahajnaA, Bar-ZakaiB, et al. Colon and rectal surgery without mechanical bowel preparation: a randomized prospective trial. Ann Surg 2003;237:363–367.
23. MuziiL, BellatiF, ZulloMA, et al. Mechanical bowel preparation before gynecologic laparoscopy: a randomized, single-blind, controlled trial. Fertil Steril 2006;85:689–693.
24. LijoiD, FerreroS, MistrangeloE, et al. Bowel preparation before laparoscopic gynaecologic surgery in benign condtions using a 1-week low fibre diet: a surgeon blind, randomized and controlled trial. Arch Gynecol Obstet 2009;280:713–718.
25. YangLC, ArdenD, LeeTT, et al. Mechanical bowel preparation for gynecologic laparoscopy: a prospective randomized trial of oral sodium phosphate solution vs single sodium phosphate enema. J Min Inv Gynecol 2011;18:149–156.
26. WonH, MaleyP, SalimS, et al. Surgical and patient outcomes using mechanical bowel preparation before laparoscopic gynecologic surgery. Obstet Gynecol 2013;121:538–546.
27. JeffcoateT, TindallV. Venous thrombosis and embolism in obstetrics and gynecology. Aust N Z J Obstet Gynaecol 1965;5:119–130.
28. Clarke-PearsonD, JelovsekF, CreasmanW. Thromboembolism complicating surgery for cervical and uterine malignancy: incidence, risk factors, and prophylaxis. Obstet Gynecol 1983;61:87–94.
29. ClaytonJ, AndersonJ, McNicolG. Preoperative prediction of postoperative deep vein thrombosis. BMJ 1976;2:910–912.
30. Clarke-PearsonD, DeLongE, SynanI, et al. Variables associated with postoperative deep venous thrombosis: a prospective study of 411 gynecology patients and creation of a prognostic model. Obstet Gynecol 1987;69:146–150.
31. KakkarV. Prevention of fatal postoperative pulmonary embolism by low dose heparin: an international multicenter trial. Lancet 1975;ii:145–151.
32. Clarke-PearsonD, DeLongE, SynanI, CreasmanW. Complications of low-dose heparin prophylaxis in gynecologic oncology surgery. Obstet Gynecol 1984;64:689–694.
33. TapsonV, HullR. Management of venous thromboembolic disease: the impact of low-molecular-weight heparin. Chest 1995;16:281–294.
34. HaasS. Recommendations for prophylaxis of venous thromboembolism: International Consensus and the American College of Chest Physicians Fifth Consensus Conference on antithrombotic therapy. Curr Opin Pulm Med 2000;6:314–320.
35. Clarke-PearsonD, SynanI, ColemanR, et al. The natural history of postoperative venous thromboembolism in gynecologic oncology: a prospective study of 283 patients. Am J Obstet Gynecol 1984;148:1051–1054.
36. ScurrJ, IbrahimS, FaberR, Le QuesneL. The efficacy of graduated compression stocking in the prevention of deep vein thrombosis. Br J Surg 1977;64:371–373.
37. SalzmanE, PloetJ, BettlemannM, et al. Intraoperative external pneumatic calf compression to afford long-term prophylaxis against deep vein thrombosis in urological patients. Surgery 1980;87:239–242.
38. NicolaidesA, FernandesE, FernandesJ, PollockA. Intermittent sequential pneumatic compression of the legs in the prevention of venous stasis and postoperative deep venous thrombosis. Surgery 1980;87:69–76.
39. Clarke-PearsonD, SynanI, HinshawW, et al. Prevention of postoperative venous thromboembolism by external pneumatic calf compression in patients with gynecologic malignancy. Obstet Gynecol 1984;63:92–98.
40. Clarke-PearsonD, CreasmanW, ColemanR, et al. Perioperative external pneumatic calf compression as thromboembolism prophylaxis in gynecologic oncology: report of a randomized controlled trial. Gynecol Oncol 1984;18:226–232.
41. MaxwellG, MyersE, Clarke-PearsonD. Cost-effectiveness of deep venous thrombosis prophylaxis in gynecologic oncology surgery. Obstet Gynecol 2000;95:206–214.
42. CreasmanW, WeedJJ. Radical hysterectomy. In SchaeferG, GragerE (eds.) Complications in Obstetrics and Gynecology Surgery. Hagerstown, MD: Harper Row, 1981, pp. 389–398.
43. HaeggerK. Problems of acute deep vein thrombosis. Angiolology 1969;20:219–222.
44. PalkoP, NamsonE, FedonikS. The early detection of deep venous thrombosis using 135I-tagged fibrinogen. Can J Surg 1964;7:215–220.
45. LensingA, PradoniP, BandjesD, et al. Detection of deep-vein thrombosis by real-time B-mode ultrasonography. N Engl J Med 1989;320:342–348.
46. AthanasoulisC. Phlebography for the Diagnosis of Deep Leg Vein Thrombosis, Prophylactic Therapy of Deep Venous Thrombosis and Pulmonary Embolism [DHEW Publication 76-886]. Washington, DC: National Institutes of Health, 1975, pp. 62–76.
47. MontgomeryK, PotterH, HelfetD. Magnetic resonance venography to evaluate the deep venous system of the pelvis in patients who have acetabular fracture. J Bone Joint Surg 1995;77:1639–1649.
48. EtchasonJ, PetzL, KeelerE, et al. The cost effectiveness of preoperative autologous blood donations. N Engl J Med 1995;332:719–724.
49. KanterM, van MaanenD, AndersK, et al. Preoperative autologous blood donations before elective hysterectomy. JAMA 1996;276:798–801.
50. National Heart, Lung, and Blood Institute Expert Panel on the Use of Autologous Blood. Transfusion alert: use of autologous blood. Transfusion 1995;35:701–711.
51. American Society of Anesthesiologists. Practice guidelines for blood component therapy. Anesthesiology 1996;84:732–747.
52. ReesM. Menorrhagia. BMJ 1987;294:759–762.
53. ShankarM, LeeC, SabinC, et al. Von Willebrand disease in women with menorrhagia: a systematic review. BJOG 2004;111:737–740.
54. KadirR, EconomidesD, SabinC, et al. Frequency of inherited bleeding disorders in women with menorrhagia. Lancet 1998;351:485–489.
55. Centers for Disease Control and Prevention. National Diabetes Factsheet 2011. (http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf, accessed 21 February 2014).
56. National Diabetes Information Clearinghouse. National Diabetes Statistics, 2011. Bethesda, MD: National Diabetes Information Clearinghousehttp://diabetes.niddk.nih.gov/dm/pubs/statistics/, accessed 21 February 2014).
57. KhanNA, GhaliWA, CaglieroE. Perioperative management of blood glucose in adults with diabetes mellitus. UpToDate 2013 (http://www.uptodate.com/contents/perioperative-management-of-blood-glucose-in-adults-with-diabetes-mellitus?source=search_result&search=Perioperative+management+of+diabetes+mellitus&selectedTitle=1~150, accessed 1 March 2014).
58. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010;33(Suppl 1):S62–S69.
59. MalmbergK, RydenL, EfendicS, et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 1995;26:57–65.
60. GallupD, GallupD, NolanT, et al. Use of a subcutaneous closed drainage system and antibiotics in obese gynecologic patients. Am J Obstet Gynecol 1996;175:358–361.
61. RasmussenK, NeumannG, LjungstromB, et al. The influence of body mass index on the prevalence of complications after vaginal and abdominal hysterectomy. Acta Obstet Gynecol Scand 2004;83:85–88.
62. SoissonA, SoperJ, BerchuckA, et al. Radical hysterectomy in obese women. Obstet Gynecol 1992;80:940–943.
63. HopkinsM, ShrinerA, ParkerM, ScottL. Panniculectomy at the time of gynecologic surgery in morbidly obese patients. Am J Obstet Gynecol 2000;182:1502–1505.
64. PearlM, ValeaF, DisilvestroP, ChalasE. Panniculectomy in morbidly obese gynecologic oncology patients. Int J Surg Invest 2000;2:59–64.
65. ThorntonK, SavelRH, GropperMA. Postoperative management of the critically ill obese patient. UpToDate 2013 (http://www.uptodate.com/contents/postoperative-management-of-the-critically-ill-obese-patient?source=search_result&search=postoperative+management+obese&selectedTitle=2~150, accessed 1 March 2014).
66. MallampatiS, GattS, GuginoL, et al. A clinical sign to predict difficult tracheal intubation: a prospective study. Can Anaesth Soc J 1985;32:429–434.
67. Von Ungern-SternbergB, RegliA, SchneiderM, et al. Effect of obesity and site of surgery on perioperative lung volumes. Br J Anaesth 2004;92:202–207.
68. VasilevSA. Perioperative and Supportive Care in Gynecologic Oncology. New York: Wiley-Liss, 2000.
69. LeeT, MarcantonioE, MangioneC, et al. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. Circulation 1999;100:1043–1049.
70. American College of Cardiology/American Heart Association. Guideline update for perioperative cardiovascular evaluation for noncardiac surgery. Executive summary. Circulation 2002;105:1257–1267.
71. ReillyD, McNeelyM, DoernerD, GreenbergD. Self-reported exercise tolerance and the risk of serious perioperative complications. Arch Intern Med 1999;159:2185–2192.
72. ManganoD. Perioperative cardiac morbidity. Anesthesiology 1990;72:153–184.
73. SandhamJD, HullRD, BrantRF, et al. A randomized, controlled trial of the use of pulmonary-artery catheters in high-risk surgical patients. N Engl J Med 2003;348:5–14.
74. CharlsonME, MacKenzieC, AlesK, et al. Surveillance for postoperative myocardial infarction after noncardiac operations. Surg Gynecol Obstet 1988;167:404–414.
75. AuerbachAD, GoldmanL.β-Blockers and reduction of cardiac events in noncardiac surgery: scientific review. JAMA 2002;287:1435–1444.
76. JohnsonMM, CondeMS. Overview of the management of postoperative pulmonary complications. UpToDate 2012 (http://www.uptodate.com/contents/overview-of-the-management-of-postoperative-pulmonary-complications?source=search_result&search=management+of+postoperative+pulmonary+complications&selectedTitle=1~35, accessed 1 March 2014).
78. SmetanaGW. Preoperative pulmonary evaluation. N Engl J Med 1999;340:937–944.
79. GilronI, TodD, GoldsteinD, et al. The relationship between movement-evoked versus spontaneous pain and peak expiratory flow after abdominal hysterectomy. Anesth Analg 2002;95:1702–1707.

References

1. KirkRM. Basic Surgical Techniques. London: Elsevier Health Sciences, 2002.
2. FarthingA. Surgery for gynaecological cancers. In ShafiMI, EarlH, TanLT (eds.) Gynaecological Oncology. Cambridge, UK: Cambridge University Press, 2010, pp. 69–78.
3. CeydeliA, RusckinskiJ, WiseL. Finding the best abdominal closure: an evidence based review of the literature. Cur Surg 2005;62:220–225.
4. MazharSB, ShafiMI. Principles of surgical technique. Obstet Gynaecol Reprod Med 2009;11:315–322.
5. Royal College of Obstetricians and Gynaecologists. Presenting Information on Risk [Clinical Governance Advice No. 7]. London: Royal College of Obstetricians and Gynaecologists, 2009.
6. Royal College of Obstetricians and Gynaecologists. Obtaining Valid Consent [Clinical Governance Advice No. 6]. London: Royal College of Obstetricians and Gynaecologists, 2008.
7. ShawskiS, WexnerSD. Oral colorectal cleansing preparation in adults. Drugs 2008;68:417–437.
8. National Institute for Health and Clinical Excellence. Surgical Site Infection: Prevention and Treatment of Surgical Site Infection. London: National Institute for Health and Clinical Excellence, 2008.
9. [No authors listed]. Antibacterial prophylaxis in surgery: 2. Urogenital, obstetric and gynaecological surgery. Drug Ther Bull 2004;42:9–13.
10. National Institute for Health and Clinical Excellence. Venous Thromboembolism. London: National Institute for Health and Clinical Excellence, 2007.
11. World Alliance for Patient Safety. WHO Surgical Safety Checklist and Implementation Manual. Geneva: World Health Organization, 2008.
12. HogstonP. Suture choice in gynaecological surgery. Obstet Gynaecol 2001;3:127.
13. ChobanPS, HecklerR, BurgeJC, FlancbaumL. Increased incidence of nosocomial infections in obese surgical patients. Am Surg 1995;61:1001–1005.
14. BlockBM, LiuSS, RowlingsonAJ, et al. Efficacy of postoperative epidural analgesia: a metaanalysis. JAMA 2003, 290:2455–2463.
15. ParkerM, WilsonM, MenziesD, et al. The SCAR-3 study: 5-year adhesion-related readmission risk following lower abdominal surgical procedures. Colorectal Dis 2005;7:551–558.
16. TingstedtB, IsakssonK, AnderssonE, et al. Prevention of abdominal adhesions: present state and what's beyond the horizon. Eur Surg Res 2007;39:259–268.
17. BolandGM, WeigelRJ. Formation and prevention of postoperative abdominal adhesions. J Surg Res 2006;132:3–12.
18. HeylandDK, MontalvoM, MacDonaldS, et al. Total parenteral nutrition in the surgical patient: a metaanalysis. Can J Surg 2001;44:102–111.
19. MeeranH, MichaelPWGrocottMPW. Clinical review: evidence-based perioperative medicine?Crit Care 2005;9:81–85.
20. FlegalKM, CarrollMD, OgdenCL, et al. Prevalence and trends in obesity among US adults, 1999–2008. JAMA 2010;3:235–241.
21. PelosiP, GregorettiC. Perioperative management of obese patients. Best Pract Res Clin Anaesthesiol 2010;2:211–225.
22. BrownCVR, VelmahosGC. The consequences of obesity on trauma, emergency surgery, and surgical critical care. World J Emerg Surg 2006;1:27.
23. American Heart Association. The Metabolic Syndrome. Washington, DC: American Heart Association (http://www.heart.org/HEARTORG/Conditions/More/MetabolicSyndrome/Metabolic-Syndrome_UCM_002080_SubHomePage.jsp, accessed 24 February 2014).
24. LevinPD, WeissmanC. Obesity, metabolic syndrome, and the surgical patient. Med Clin North Am 2009;93:1049–1063.
25. UK Department of Health. Enhanced Recovery Partnership Programme. London: Department of Health, 2011 (https://www.gov.uk/government/publications/enhanced-recovery-partnership-programme, accessed 24 February 2014).